Clinical trials: Mild to Severe Hypertension
Mild to Severe Hypertension
MK0954A-264 Filter Study (0954A-264)(COMPLETED)
To compare the blood pressure lowering efficacy, safety and tolerability of a combination drug to a single drug taken once daily in patients with uncontrolled blood pressure following a 4-week filter on the single therapy product.
- Trial name
- NCT00307060
- Testing
- MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks, losartan / Duration of Treatment: 6 weeks
- Volunteers
- 274 people
- Sponsor
- Organon and Co
Hypertension
Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension
This study assesses the efficacy and safety of co-administration of olmesartan medoxomil plus amlodipine in mild to severe hypertensive patients older than 18 years of age
- Trial name
- NCT00185133
- Testing
- Olmesartan medoxomil, Amlodipine
- Where
- 139 sites in United States
- Volunteers
- 1,900 people
- Sponsor
- Daiichi Sankyo
Hypertension
Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis
To evaluate the safety and efficacy, in particular with regard to renal function of telmisartan at the doses of 40 mg and 80 mg in hypertensive patients with moderate to endstage renal impairment after 12 weeks of treatment
- Trial name
- ESPRIT (NCT02178306)
- Testing
- Telmisartan low dose, Telmisartan high dose
- Volunteers
- 82 people
- Sponsor
- Boehringer Ingelheim
Preeclampsia and Eclampsia, Preeclampsia Severe
Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
The purpose of this study is to 1. Identify a cut-off for the ratio of the serum proteins soluble FMS-like Tyrosine Kinase 1 (sFLT-1) and placental growth factor (PlGF) that identifies women will who develop preeclampsia with…
- Conditions
- Preeclampsia and Eclampsia, Preeclampsia Severe, Gestational Hypertension, Chronic Hypertension in Obstetric Context
- Trial name
- PRAECIS (NCT03815110)
- Where
- 18 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- Cedars-Sinai Medical Center
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal…
- Trial name
- NCT04200573
- Testing
- Ampreloxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma